FDA Announces Second Approval of Gavreto
New indication focuses on metastatic rearranged during transfection fusion-positive non-small cell lung cancer.
After previously approving Gavreto (pralsetinib) for non-small cell lung cancer (NSCLC) in late 2020, the FDA has announced an additional approval for metastatic rearranged during transfection (RET) fusion-positive NSCLC. Backed by an FDA-approved test, efficiency was demonstrated in a total of 237 patients with locally advanced or metastatic RET fusion-positive NSCLC. Patients received pralsetinib until disease progression or unacceptable toxicity, according to an FDA press release.
In the same press release, the FDA stated that the recommended pralsetinib dose is 400 mg orally once daily, to be taken on an empty stomach.
Reference: FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions. FDA. August 9, 2023. Accessed August 10, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pralsetinib-non-small-cell-lung-cancer-ret-gene-fusions
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Social Media's Influence on Young Women's Reproductive Decisions
February 20th 2025In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.
